Fetching results...
0 items found

A1183: Efficacy and safety of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) by metastatic burden: Subgroup analyses of ARASENS

Prof. B. (Bertrand) Tombal
Tombal B.1, Saad F.2, Fizazi K.3, Sternberg C.N.4, Crawford E.D.5, Gratzke C.6, Grabbert M.6, Vilaseca A.7, Shore N.8, Kopyltsov E.9, Bögemann M.10, Kapur S.11, Srinivasan S.12, Verholen F.13, Kuss I.14, Joensuu H.15, Smith M.R.16, Hussain M.17
1Cliniques Universitaires Saint-Luc, Dept. of Urology, Brussels, Belgium, 2University of Montreal Hospital Center, Dept. of Urology, Montreal, Canada, 3University of Paris-Saclay, Institut Gustave Roussy, Villejuif, France, 4Englander Institute for Precision Medicine, Weill Cornell Dept. of Medicine, New York, United States of America, 5UC San Diego School of Medicine, Dept. of Urology, San Diego, United States of America, 6University Hospital Freiburg, Dept. of Urology, Freiburg, Germany, 7Hospital Clínic de Barcelona, Uro-oncology Unit, Barcelona, Spain, 8Carolina Urologic Research Center, Genesis Care, Dept. of Urology, Myrtle Beach, United States of America, 9Clinical Oncological Dispensary of Omsk Region, Dept. of Oncology, Omsk, Russia, 10Münster University Medical Center, Dept. of Urology, Münster, Germany, 11Bayer SAE, Dept. of Medical Affairs, Singapore, Singapore, 12Bayer HealthCare Pharmaceuticals Inc, Dept. of Statistics, Whippany, United States of America, 13Bayer Consumer Care AG, Dept. of Medical Affairs, Basel, Switzerland, 14Bayer AG, Clinical Development, Berlin, Germany, 15Orion Corporation, Clinical Development, Espoo, Finland, 16Massachusetts General Hospital Cancer Center, Dept. of Hematology, Dept. of Oncology, Boston, United States of America, 17Northwestern University, Feinberg School of Medicine, Chicago, United States of America
38th Annual EAU Congress
Date – Time - Location
13 March 2023, 14:15 - 15:45, Pink Area, Coral 4
Abstract Session 62 - Novel prognostic factors and optimal treatment for patients with metastatic prostate cancer
Prostate Cancer, metastatic - Treatment, Drug Treatment
  • © 2023 European Association of Urology
  • Disclaimer